Sean McClain is the Founder and CEO of Absci, a leading generative AI Drug Creation company with a mission to create better biologics for patients, faster.
Sean embodies entrepreneurial spirit, having built Absci from basement lab to a publicly traded company and continuing to strive towards his vision to create therapeutics at the click of a button. Under his leadership, Absci scaled to over 200 employees, raised over $525M in capital, established a growing number of industry-leading partnerships, and built an Integrated Drug Creation Platform that merges bleeding-edge generative AI models with proprietary high-throughput wet-lab data.
Sean studied biochemistry and molecular biology at the University of Arizona and has been the recipient of numerous recognitions for his entrepreneurship and innovation. He serves as a board member for the Oregon Translational Research and Development Institute, and Life Science Washington